ArticleDiscover oncology2025
Novel radiation-derived gene blueprint stratifying patients with breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is a prevalent global malignancy with a high recurrence rate. The effectiveness of predictive, preventive, and personalized treatment strategies is limited by a lack of reliable prognostic biomarkers. Radiotherapy significantly reduces breast cancer recurrence risk and prolongs patients' lives. However, the role of radiation-related genes in breast cancer remains unclear. MATERIALS AND
methodsDifferentially expressed radiation-related genes were identified through analysis of the BRCA gene expression matrix between radiation and non-radiation groups. Multi-omics investigation, including bulk and single-cell RNA sequencing, was conducted to explore these genes in breast cancer. A risk model was developed using random forest, stepAIC, and LASSO Cox regression analyses to predict prognosis, immune cell infiltration, immunotherapy response, and targeted drug sensitivity based on radiation-related gene expression profiles. Functional differences were assessed via Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analyses.
resultsWe identified 133 radiation-related differentially expressed genes (DEGs), with 26 hub genes selected via LASSO and random forest models. Single-cell analysis revealed enrichment of radiation-related scores primarily in malignant cells. The radiation-related risk model, validated in the METABRIC dataset and an independent prognostic indicator in the TCGA-BRCA cohort, showed that low-risk patients had higher overall survival rates than high-risk patients. Risk scores correlated with immune infiltration, and low-risk patients exhibited greater immunotherapy response based on immune checkpoint gene expression. Drug sensitivity to gemcitabine, lapatinib, methotrexate, and doxorubicin varied across risk groups.
conclusionTo put it briefly, a strong efficient risk model was created to forecast prognosis, TME features, reactions to immunotherapy targeted medications in BRCA. This might lead to new understandings of individualized accurate treatment approaches. To facilitate clinical application, we have developed an R package and Excel-based calculator tool that enables clinicians to easily calculate patient risk scores using the 8-gene signature. These tools, along with detailed usage instructions, are freely available in the supplementary materials and GitHub repository.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.